In 2016, the Osteoarthritis Research Society International (OARSI) reported that osteoarthritis (OA) is the third most prevalent condition causing disability globally. Currently, there is no cure for OA, which is the most prevalent form of arthritis both in the U.S. and worldwide. Continue reading Our Reach Expands With Global Osteoarthritis Management
Biotech giant Sanofi Genzyme has initiated a voluntary product recall for one lot of Synvisc-One, a brand of hyaluronic acid. The lot, which was found to contain contamination, has been linked to an unexpected increase in side effects. In an urgent “product hold” letter, doctors, clinics and pharmacies who received syringes from that lot were instructed to immediately stop using the injections on patients until the company can investigate.
Continue reading Synvisc-One Injections Recalled
With several years gone by since the last drug for osteoarthritis (OA) was approved, the 27 million Americans with OA are ready to hear Yes when it comes to new therapies and diagnostic tests for OA.
Fortunately, this past May, Arthritis Foundation met with Janet Woodcock, the Director of the Center for Drug Evaluation and Research (CDER) at the Food and Drug Administration (FDA) and her colleagues. A representative from the Center for Biologics Evaluation and Research (CBER) also attended the meeting. The goal of the meeting was to discuss how the organizations can work together to design and implement new approaches to clinical trials that will accelerate the improvement of health outcomes for people with OA.